(2005). Heneka MT: The oral antidiabetic pioglitazone protects from neurodegenerative and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice.
(2004). Herrero MT: Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 years after MPTP exposure. Glia
(2010). Hong JS: Neuroinflammation is a key player in Parkinson’s disease and a prime target for therapy.
(2009). Hunot S: Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol
(2007). Inflammation induces mitochondirial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system.
Insulin Resistance Intervention after Stroke.
Iwamoto T: Efficacy of PPAR-gama agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging .
(1997). Jagust WJ: PET studies of functional compensation in a primate modle of Parkinson’s disease. NeuroReport
(2004). JB: Protection by pioglitazone in the MPTP model of Parkinson’s disease correlates with I kappa B alpha induction and block of NFkappa B and iNOS activation.
(2007). Kim-Mitsuyama S: Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure. Stroke
(1998). Kordower JH: Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys.
(2000). MR: Thiazolidinediones: a comparative review of approved uses. Diabetes Technol Ther
(2007). Nonhuman primate models of Parkinson’s disease.
(1991). Pakkenberg H: The absolutely number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson’s disease estimated with an unbiased stereological method.
(2008). Physician’s Desk Reference. 64 edition.
(1994). Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys. Diabetes
(2007). PJ: A model of experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice for Swanson et al.
(2003). Presence of Reactive Microglia in Monkey Substantia Nigra Years after 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Administration. Ann Neurol
(2008). Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats. Neurosci Lett
(2006). Realistic expectations for treatment success in Alzheimer’s disease.
(2006). Saraphanchotiwitthaya A: High-performance liquid chromatographic method for the determination of pioglitazone in human plasma using ultraviolet detection and its application to a pharmacokinetic study.
(1986). Schmuff NR: The pharmacology of the parkinsonian syndrome producing neurotoxin MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and structurally related compounds. Med Res Rev
(1988). Sokoloff L: Administration of MPTP acutely increases glucose utilization in the substantia nigra of primates. Brain Res
(1985). SP: Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects. Life Sci
(1988). SP: Metabolism of [14C]MPTP in mouse and monkey implicates MPP+, and not bound metabolites, as the operative neurotoxin. Chem Res Toxicol
Tansey MJ: Modeling neuroinflammatory pathogenesis of Parkinson’s disease.
(2011). Tarelli R: Parkinson’s disease and systemic inflammation. Parkinsons Dis
(2007). Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J Pharmacol Exp Ther
(2008). Virley DJ: The PPAR-gamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson’s disease through inhibition of monoamine oxidase B. Br J Pharmacol
(2005). Youdim MB: Mechanisms of neuroprotective actions of the anti-Parkinsonian drug resagilline and its derivitives. Brain Research Reviews
(2010). Zhang HL: Neuroprotective effects of pioglitazone in a rat model of permanent focal cerebral ischemia are associated with peroxisome proliferatoractivated receptor gamma-mediated suppression of nuclear factor kappa-B signaling pathway. Neuroscience